Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

Purpose: In this study, we assessed the specific role of BRAF(V600E) signaling in modulating the expression of immune regulatory genes in melanoma, in addition to analyzing downstream induction of immune suppression by primary human melanoma tumor-associated fibroblasts (TAF). Experimental Design: Primary human melanocytes and melanoma cell lines were transduced to express WT or V600E forms of BRAF, followed by gene expression analysis. The BRAF(V600E) inhibitor vemurafenib was used to confirm targets in BRAF(V600E)-positive melanoma cell lines and in tumors from melanoma patients undergoing inhibitor treatment. TAF lines generated from melanoma patient biopsies were tested for their ability to inhibit the function of tumor antigen-specific T cells, before and following treatment with BRAF(V600E)-upregulated immune modulators. Transcriptional analysis of treated TAFs was conducted to identify potential mediators of T-cell suppression. Results: Expression of BRAF(V600E) induced transcription of interleukin 1 alpha (IL-1α) and IL-1β in melanocytes and melanoma cell lines. Further, vemurafenib reduced the expression of IL-1 protein in melanoma cell lines and most notably in human tumor biopsies from 11 of 12 melanoma patients undergoing inhibitor treatment. Treatment of melanoma-patient–derived TAFs with IL-1α/β significantly enhanced their ability to suppress the proliferation and function of melanoma-specific cytotoxic T cells, and this inhibition was partially attributable to upregulation by IL-1 of COX-2 and the PD-1 ligands PD-L1 and PD-L2 in TAFs. Conclusions: This study reveals a novel mechanism of immune suppression sensitive to BRAF(V600E) inhibition, and indicates that clinical blockade of IL-1 may benefit patients with BRAF wild-type tumors and potentially synergize with immunotherapeutic interventions. Clin Cancer Res; 18(19); 5329–40. ©2012 AACR.

[1]  J. Wilmott,et al.  Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.

[2]  T. Choueiri,et al.  Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. , 2011, Critical reviews in oncology/hematology.

[3]  Erin F. Simonds,et al.  Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum , 2011, Science.

[4]  D. Mougiakakos,et al.  Camouflage and sabotage: tumor escape from the immune system , 2011, Cancer Immunology, Immunotherapy.

[5]  T. Choueiri,et al.  Hematologic toxicities in cancer patients treated with the multityrosine kinase sorafenib: A meta-analysis of clinical trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Adams,et al.  Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. , 2011, Immunotherapy.

[7]  D. Kranz.  Faculty Opinions recommendation of Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. , 2010 .

[8]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α , 2010, Science.

[9]  S. Mustjoki,et al.  Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy , 2010, European journal of haematology.

[10]  P. Coulie,et al.  Interleukins 1α and 1β secreted by some melanoma cell lines strongly reduce expression of MITF‐M and melanocyte differentiation antigens , 2010, International journal of cancer.

[11]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[12]  D. Mougiakakos,et al.  Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. , 2010, Cancer research.

[13]  Kristian Pietras,et al.  Hallmarks of cancer: interactions with the tumor stroma. , 2010, Experimental cell research.

[14]  S. Ostrand-Rosenberg.  Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity , 2010, Cancer Immunology, Immunotherapy.

[15]  B. Shalmon,et al.  Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients , 2010, Clinical Cancer Research.

[16]  Peter Olson,et al.  Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. , 2010, Cancer cell.

[17]  Y. Carmi,et al.  Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation , 2010, Proceedings of the National Academy of Sciences.

[18]  P. Hwu,et al.  MART-1–Specific Melanoma Tumor-Infiltrating Lymphocytes Maintaining CD28 Expression Have Improved Survival and Expansion Capability Following Antigenic Restimulation In Vitro , 2009, The Journal of Immunology.

[19]  P. Queirolo,et al.  Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[20]  J. Reis-Filho,et al.  Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma , 2009, Pigment cell & melanoma research.

[21]  R. Xiang,et al.  Cancer Associated Fibroblasts Promote Tumor Growth and Metastasis by Modulating the Tumor Immune Microenvironment in a 4T1 Murine Breast Cancer Model , 2009, PloS one.

[22]  G. Watanabe,et al.  Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2009, Clinical Cancer Research.

[23]  D. Green,et al.  Immunogenic and tolerogenic cell death , 2009, Nature Reviews Immunology.

[24]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[25]  L. Zitvogel,et al.  The immunogenicity of tumor cell death , 2009, Current opinion in oncology.

[26]  L. Zitvogel,et al.  The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.

[27]  R. Dummer,et al.  AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. , 2008 .

[28]  W. Franklin,et al.  Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Einsele,et al.  Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib , 2008, Clinical Cancer Research.

[30]  E. Voronov,et al.  Is interleukin‐1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? , 2008, Immunological reviews.

[31]  J. Lukens,et al.  Blockade of PD-1/B7-H1 Interaction Restores Effector CD8+ T Cell Responses in a Hepatitis C Virus Core Murine Model1 , 2008, The Journal of Immunology.

[32]  J. Leips,et al.  Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. , 2007, Cancer research.

[33]  P. Hwu,et al.  Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy , 2007, Clinical Cancer Research.

[34]  K. Lim,et al.  Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. , 2007, Genes & development.

[35]  S. Akira,et al.  Identification of a key pathway required for the sterile inflammatory response triggered by dying cells , 2007, Nature Medicine.

[36]  R. J. Kelleher,et al.  Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells1 , 2007, The Journal of Immunology.

[37]  P. Hwu,et al.  Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms , 2006, Clinical Cancer Research.

[38]  Y. Kawakami,et al.  The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells , 2006, The Journal of experimental medicine.

[39]  M. Nishibori,et al.  E prostanoid 2 (EP2)/EP4‐mediated suppression of antigen‐specific human T‐cell responses by prostaglandin E2 , 2006, Immunology.

[40]  P. Hwu,et al.  Immunosuppression in Melanoma Immunotherapy: Potential Opportunities for Intervention , 2006, Clinical Cancer Research.

[41]  J. Leips,et al.  Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression1 , 2006, The Journal of Immunology.

[42]  K. Harii,et al.  Correlation between age and the secretions of melanocyte‐stimulating cytokines in cultured keratinocytes and fibroblasts , 2005, The British journal of dermatology.

[43]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[45]  C. Springer,et al.  V599EB-RAF is an Oncogene in Melanocytes , 2004, Cancer Research.

[46]  B. Sipos,et al.  Tumor Stroma Interactions Induce Chemoresistance in Pancreatic Ductal Carcinoma Cells Involving Increased Secretion and Paracrine Effects of Nitric Oxide and Interleukin-1β , 2004, Cancer Research.

[47]  Stan Pounds,et al.  Estimating the Occurrence of False Positives and False Negatives in Microarray Studies by Approximating and Partitioning the Empirical Distribution of P-values , 2003, Bioinform..

[48]  S. Tóth,et al.  Autocrine and paracrine regulation by cytokines and growth factors in melanoma. , 2000, Cytokine.

[49]  J. Roth,et al.  Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS. , 1999, Cancer research.

[50]  M. Kulke,et al.  Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  Chen Dong,et al.  MAP kinases in the immune response. , 2002, Annual review of immunology.

[52]  N. Ordóñez,et al.  Interleukin-1 production in tumor cells of human melanoma surgical specimens. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.